Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung K.J.; Khan P.; Franke M.F.; Ahmed S.; Aiylchiev S.; Alam M.; Putri F.A.; Bastard M.; Docteur W.; Gottlieb G.; Hewison C.; Islam S.; Khachatryan N.; Kotrikadze T.; Khan U.; Kumsa A.; Lecca L.; Tassew Y.M.; Melikyan N.; Naing Y.Y.; Oyewusi L.; Rich M.; Wanjala S.; Yedilbayev A.; Huerga H.; Mitnick C.D. · Clinical Infectious Diseases (2020) · DOI: 10.1093/cid/ciz1084

Resumen

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.